GeneDx Holdings (WGS) Stock Overview
A genomics company, provides genetic testing services. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
WGS Community Fair Values
Create NarrativeSee what 52 others think this stock is worth. Follow their fair value or set your own to get alerts.
GeneDx Holdings Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$66.20 |
| 52 Week High | US$170.87 |
| 52 Week Low | US$55.17 |
| Beta | 2.19 |
| 1 Month Change | -19.27% |
| 3 Month Change | -49.96% |
| 1 Year Change | -17.27% |
| 3 Year Change | 512.16% |
| 5 Year Change | -86.63% |
| Change since IPO | -79.53% |
Recent News & Updates
Recent updates
GeneDx: The Growth Story Isn't Dead, It's Changing (Rating Upgrade)
Feb 24GeneDx Holdings Corp. (NASDAQ:WGS) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
Jan 21
Shareholders Will Be Pleased With The Quality of GeneDx Holdings' (NASDAQ:WGS) Earnings
Nov 06News Flash: Analysts Just Made A Captivating Upgrade To Their GeneDx Holdings Corp. (NASDAQ:WGS) Forecasts
Aug 07Why Investors Shouldn't Be Surprised By GeneDx Holdings Corp.'s (NASDAQ:WGS) 28% Share Price Surge
Jun 27Health Check: How Prudently Does GeneDx Holdings (NASDAQ:WGS) Use Debt?
Jun 24With A 26% Price Drop For GeneDx Holdings Corp. (NASDAQ:WGS) You'll Still Get What You Pay For
May 02GeneDx: Strengthening Leadership In Genomic Diagnostics
Apr 28
Expanding Exome And Genome Testing Will Unlock Future Potential
GeneDx's focus on expanding genetic testing access and launching user-friendly products aims to significantly enhance revenue growth and market adoption.Is GeneDx Holdings Corp. (NASDAQ:WGS) Trading At A 31% Discount?
Apr 14Is GeneDx Holdings (NASDAQ:WGS) Using Too Much Debt?
Mar 17GeneDx Holdings: There Is Upside Potential, But Price Tag Is Rich
Mar 12Why Investors Shouldn't Be Surprised By GeneDx Holdings Corp.'s (NASDAQ:WGS) 32% Share Price Surge
Feb 27Shareholder Returns
| WGS | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 16.0% | 4.5% | 3.5% |
| 1Y | -17.3% | -24.6% | 31.0% |
Return vs Industry: WGS exceeded the US Healthcare industry which returned -27.3% over the past year.
Return vs Market: WGS underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| WGS volatility | |
|---|---|
| WGS Average Weekly Movement | 10.9% |
| Healthcare Industry Average Movement | 7.5% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: WGS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: WGS's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,300 | Katherine Stueland | www.genedx.com |
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.
GeneDx Holdings Corp. Fundamentals Summary
| WGS fundamental statistics | |
|---|---|
| Market cap | US$1.94b |
| Earnings (TTM) | -US$21.02m |
| Revenue (TTM) | US$427.54m |
Is WGS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WGS income statement (TTM) | |
|---|---|
| Revenue | US$427.54m |
| Cost of Revenue | US$129.36m |
| Gross Profit | US$298.18m |
| Other Expenses | US$319.20m |
| Earnings | -US$21.02m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.72 |
| Gross Margin | 69.74% |
| Net Profit Margin | -4.92% |
| Debt/Equity Ratio | 17.1% |
How did WGS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/04 20:31 |
| End of Day Share Price | 2026/04/02 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GeneDx Holdings Corp. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |
| William Bonello | Craig-Hallum Capital Group LLC |